Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.69 | N/A | -11.29% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.69 | N/A | -11.29% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook without providing specific guidance. They emphasized the importance of ongoing clinical trials.
Management did not provide specific guidance for future quarters.
The focus remains on advancing clinical programs.
Protagonist Therapeutics reported a wider-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term performance. The stock reaction reflects uncertainty in the market regarding future developments.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Aug 2, 2021